Compare AIRE & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIRE | IMMX |
|---|---|---|
| Founded | 2021 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 59.2M | 306.2M |
| IPO Year | N/A | 2021 |
| Metric | AIRE | IMMX |
|---|---|---|
| Price | $0.43 | $5.31 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $2.00 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 5.8M | 1.5M |
| Earning Date | 11-12-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,149,567.00 | N/A |
| Revenue This Year | $456.19 | N/A |
| Revenue Next Year | $105.16 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 994.18 | N/A |
| 52 Week Low | $0.14 | $1.34 |
| 52 Week High | $2.89 | $7.73 |
| Indicator | AIRE | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 42.04 | 49.94 |
| Support Level | $0.43 | $5.46 |
| Resistance Level | $0.60 | $6.09 |
| Average True Range (ATR) | 0.04 | 0.58 |
| MACD | -0.00 | -0.17 |
| Stochastic Oscillator | 10.43 | 2.02 |
ReAlpha Tech Corp is a real estate technology company. The group is engaged in an end-to-end commission-free homebuying platform. It develops and utilizes its artificial intelligence-focused technology stack to empower retail investor participation in short-term rental properties, which are real estate units listed for a rental term. It provides short-term rental investment opportunities to everyday investors. The company has developed technologies and tools that allow for the analysis of short-term rental properties using AI to provide insight into that property's potential profitability and ways to increase such profitability. The company's reportable segments are; Platform Services and the Rental business segment.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.